MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7899
-0.0201
-2.48%
After Hours: 0.7946 +0.0047 +0.60% 17:53 10/20 EDT
OPEN
0.8103
PREV CLOSE
0.8100
HIGH
0.8103
LOW
0.7650
VOLUME
391.01K
TURNOVER
--
52 WEEK HIGH
1.970
52 WEEK LOW
0.3230
MARKET CAP
48.74M
P/E (TTM)
-2.1447
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Moleculin reports additional positive interim results in adult glioblastoma trial
Moleculin Biotech (MBRX) announces additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma ((GBM)). This supports the progression of the
Seekingalpha · 10/13 12:57
Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma (GBM). This supports the progression of the trial to the fourth and final dose escalation cohort. Three patients have completed treatment in the third cohort at a dose level of 8 mg/kg with no adverse events related to WP1066 and the study will now proceed to the next higher dose of 16 mg/kg.
PR Newswire · 10/13 12:30
Moleculin Biotech Announces Additional Prelim. Data From Phase 1 Glioblastoma Clinical Trial
HOUSTON, Oct. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant
Benzinga · 10/13 11:31
Moleculin pipeline candidates show potential activity against HIV
Nano cap Moleculin Biotech (MBRX) perks up 6% premarket on average volume in reaction to its announcement that pipeline candidates WP1096 and WP1097, which have shown activity against SARS-CoV-2, also showed activity
Seekingalpha · 10/06 12:10
Moleculin Announces Its WP1096 And WP1097 Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV; Also Show Activity In Zika And Dengue Fever
HOUSTON, October 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet
Benzinga · 10/06 11:32
Moleculin Appoints Elizabeth Cermak to Board of Directors
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, today announced the appointment of Elizabeth (Liz) Cermak, an accomplished life
PR Newswire · 10/05 12:30
Moleculin's WP1066 shows encouraging action in early-stage pediatric brain tumor study
Moleculin Biotech ([[MBRX]] +3.4%) announced interim first cohort data from the Emory University physician-sponsored Phase 1 trial, with WP1066 (AflacST1901) for the treatment of childhood brain tumors.First three patients received WP1066 dose level of 4 mg/kg
Seekingalpha · 10/01 15:41
Moleculin Biotech Reports Interim Results In Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University: WP1066 Showed Activity In Diffuse Intrinsic Pontine Glioma
Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and
Benzinga · 10/01 11:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBRX. Analyze the recent business situations of Moleculin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MBRX stock price target is 3.333 with a high estimate of 5.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 4.13M
% Owned: 6.69%
Shares Outstanding: 61.70M
TypeInstitutionsShares
Increased
5
313.81K
New
18
-28.52K
Decreased
3
1.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.